Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02858973 · ClinicalTrials.gov registry record · Phase 1

A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of Q203 in Normal Healthy Male and Female Volunteers

A Phase 1 study, sponsored by Qurient Co..

Completed
Registry status
Phase 1
Development phase
47
Enrollment target

NCT02858973 is a Phase 1 study that has completed, run by Qurient Co.. The registered enrollment target is 47 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02858973, a Phase 1 study, has completed, sponsored by Qurient Co..

COMPLETED
Registry status
Phase 1
Development phase
47 participants
Enrollment target

Study Summary

This is randomized, double-blind, placebo-controlled, multiple ascending dose study of Q203 in healthy volunteers conducted at one study center in the United States

Interventions

  • DRUG Placebo
  • DRUG Q203

Trial Details

FieldValue
Enrollment Target 47 participants
Start Date 2016-08
Est. Completion 2018-05-08
Phase Phase 1

Sponsor

Qurient Co.

7 total trials

What the Registry Record Tells You About NCT02858973

The ClinicalTrials.gov registry entry for NCT02858973 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Qurient Co., which has 7 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02858973 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02858973 about?

NCT02858973 is a clinical study titled "A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of Q203 in Normal Healthy Male and Female Volunteers". This is randomized, double-blind, placebo-controlled, multiple ascending dose study of Q203 in healthy volunteers conducted at one study center in the United States

What is the current status of trial NCT02858973?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2016-08. Estimated completion is 2018-05-08.

What interventions are being tested in trial NCT02858973?

The interventions under investigation include: Placebo (DRUG), Q203 (DRUG).

Who is sponsoring clinical trial NCT02858973?

This trial is sponsored by Qurient Co., which has 7 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.